1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Drugs In Development, 2022, provides an overview of the Vitiligo (Dermatology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 2, 1, 2, 15 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.
Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Vitiligo - Overview
- Vitiligo - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Vitiligo - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Vitiligo - Companies Involved in Therapeutics Development
- Vitiligo - Drug Profiles
- Vitiligo - Dormant Projects
- Vitiligo - Discontinued Products
- Vitiligo - Product Development Milestones
- Featured News & Press Releases
- Jul 19, 2022: US FDA grants approval to Incyte’s Opzelura cream for vitiligo treatment
- May 10, 2022: Clinuvel progresses vitiligo study
- May 09, 2022: CLINUVEL progresses vitiligo treatment program
- Mar 26, 2022: Incyte announces 52-week data from the phase 3 TRuE-V program evaluating ruxolitinib cream (Opzelura) in patients with vitiligo
- Mar 18, 2022: Incyte announces multiple abstracts from its dermatology portfolio have been accepted for presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
- Mar 14, 2022: Incyte announces U.S. FDA has extended the supplemental New Drug Application review period for ruxolitinib cream (Opzelura) for the treatment of vitiligo
- Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
- Dec 20, 2021: SCENESSE as vitiligo monotherapy
- Dec 14, 2021: Incyte announces acceptance and Priority Review of sNDA for ruxolitinib cream (Opzelura) as a treatment for patients with vitiligo
- Oct 28, 2021: Incyte announces the validation of the European Marketing authorization application for Ruxolitinib Cream in Vitiligo
- Oct 02, 2021: Incyte announces full results from phase 3 TRuE-V program evaluating ruxolitinib cream (Opzelura) in patients with vitiligo
- Sep 13, 2021: Incyte announces ruxolitinib cream data accepted for presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
- Jul 01, 2021: Arcutis provides update on phase 2a clinical trial evaluating ARQ-252 cream as a potential treatment for vitiligo
- Jul 01, 2021: Arcutis provides update on phase 2a clinical trial evaluating ARQ-252 cream as a potential treatment for vitiligo
- May 18, 2021: Incyte’s ruxolitinib meets endpoints in Phase III trials for vitiligo
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Vitiligo, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Vitiligo - Pipeline by 2A Pharma AB, 2022
- Vitiligo - Pipeline by AbbVie Inc, 2022
- Vitiligo - Pipeline by Ahammune Biosciences Pvt Ltd, 2022
- Vitiligo - Pipeline by Alexion Pharmaceuticals Inc, 2022
- Vitiligo - Pipeline by Almirall SA, 2022
- Vitiligo - Pipeline by Amgen Inc, 2022
- Vitiligo - Pipeline by AnaptysBio Inc, 2022
- Vitiligo - Pipeline by AnTolRx Inc, 2022
- Vitiligo - Pipeline by APIRx Pharmaceuticals USA LLC, 2022
- Vitiligo - Pipeline by Arrien Pharmaceuticals LLC, 2022
- Vitiligo - Pipeline by Avotres Inc, 2022
- Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
- Vitiligo - Pipeline by Elixiron Immunotherapeutics Inc, 2022
- Vitiligo - Pipeline by Forte Biosciences Inc, 2022
- Vitiligo - Pipeline by HysensBio Corp, 2022
- Vitiligo - Pipeline by Incyte Corp, 2022
- Vitiligo - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Vitiligo - Pipeline by JN Biosciences LLC, 2022
- Vitiligo - Pipeline by Pfizer Inc, 2022
- Vitiligo - Pipeline by Radikal Therapeutics Inc, 2022
- Vitiligo - Pipeline by Rhizen Pharmaceuticals SA, 2022
- Vitiligo - Pipeline by Shanghai Icure Biotechnology Co Ltd, 2022
- Vitiligo - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Vitiligo - Pipeline by TagCyx Biotechnologies, 2022
- Vitiligo - Pipeline by Technoderma Medicines Inc, 2022
- Vitiligo - Pipeline by Temprian Therapeutics Inc, 2022
- Vitiligo - Pipeline by TWi Biotechnology Inc, 2022
- Vitiligo - Pipeline by Villaris Therapeutics Inc, 2022
- Vitiligo - Pipeline by VYNE Therapeutics Inc, 2022
- Vitiligo - Dormant Projects, 2022
- Vitiligo - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Vitiligo, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2A Pharma AB
- AbbVie Inc
- Ahammune Biosciences Pvt Ltd
- Alexion Pharmaceuticals Inc
- Almirall SA
- Amgen Inc
- AnaptysBio Inc
- AnTolRx Inc
- APIRx Pharmaceuticals USA LLC
- Arrien Pharmaceuticals LLC
- Avotres Inc
- Clinuvel Pharmaceuticals Ltd
- Elixiron Immunotherapeutics Inc
- Forte Biosciences Inc
- HysensBio Corp
- Incyte Corp
- Jiangsu Hengrui Medicine Co Ltd
- JN Biosciences LLC
- Pfizer Inc
- Radikal Therapeutics Inc
- Rhizen Pharmaceuticals SA
- Shanghai Icure Biotechnology Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- TagCyx Biotechnologies
- Technoderma Medicines Inc
- Temprian Therapeutics Inc
- TWi Biotechnology Inc
- Villaris Therapeutics Inc
- VYNE Therapeutics Inc
